158 related articles for article (PubMed ID: 27252417)
1. Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Sestak I; Zhang Y; Schroeder BE; Schnabel CA; Dowsett M; Cuzick J; Sgroi D
Clin Cancer Res; 2016 Oct; 22(20):5043-5048. PubMed ID: 27252417
[TBL] [Abstract][Full Text] [Related]
2. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
[TBL] [Abstract][Full Text] [Related]
3. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
[TBL] [Abstract][Full Text] [Related]
4. A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR
Zhang Y; Schroeder BE; Jerevall PL; Ly A; Nolan H; Schnabel CA; Sgroi DC
Clin Cancer Res; 2017 Dec; 23(23):7217-7224. PubMed ID: 28939745
[No Abstract] [Full Text] [Related]
5. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Buus R; Sestak I; Kronenwett R; Denkert C; Dubsky P; Krappmann K; Scheer M; Petry C; Cuzick J; Dowsett M
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27400969
[TBL] [Abstract][Full Text] [Related]
6. Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Buus R; Sestak I; Barron S; Loughman T; Fender B; Ruiz CL; Dynoodt P; Wang CA; O'Leary D; Gallagher WM; Dowsett M; Cuzick J
Clin Cancer Res; 2020 Feb; 26(3):623-631. PubMed ID: 31641007
[TBL] [Abstract][Full Text] [Related]
7. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Dowsett M; Cuzick J; Wale C; Forbes J; Mallon EA; Salter J; Quinn E; Dunbier A; Baum M; Buzdar A; Howell A; Bugarini R; Baehner FL; Shak S
J Clin Oncol; 2010 Apr; 28(11):1829-34. PubMed ID: 20212256
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Dowsett M; Sestak I; Lopez-Knowles E; Sidhu K; Dunbier AK; Cowens JW; Ferree S; Storhoff J; Schaper C; Cuzick J
J Clin Oncol; 2013 Aug; 31(22):2783-90. PubMed ID: 23816962
[TBL] [Abstract][Full Text] [Related]
10. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
[TBL] [Abstract][Full Text] [Related]
12. Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
Jerevall PL; Brock J; Palazzo J; Wieczorek T; Misialek M; Guidi AJ; Wu Y; Erlander MG; Zhang Y; Schnabel CA; Goss PE; Horick N; Sgroi DC
Breast Cancer Res Treat; 2019 Jan; 173(2):375-383. PubMed ID: 30350269
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
14. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
16. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Aihara T; Yokota I; Hozumi Y; Aogi K; Iwata H; Tamura M; Fukuuchi A; Makino H; Kim R; Andoh M; Tsugawa K; Ohno S; Yamaguchi T; Ohashi Y; Watanabe T; Takatsuka Y; Mukai H
Breast Cancer Res Treat; 2014 Nov; 148(2):337-43. PubMed ID: 25318924
[TBL] [Abstract][Full Text] [Related]
18. Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Pece S; Sestak I; Montani F; Tillhon M; Maisonneuve P; Freddi S; Chu K; Colleoni M; Veronesi P; Disalvatore D; Viale G; Buus R; Cuzick J; Dowsett M; Di Fiore PP
Eur J Cancer; 2022 Mar; 164():52-61. PubMed ID: 35172273
[TBL] [Abstract][Full Text] [Related]
19. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Lyman GH; Cosler LE; Kuderer NM; Hornberger J
Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk of late recurrence in hormone-responsive breast cancer.
Cufer T
Ann Oncol; 2007 Sep; 18 Suppl 8():viii18-25. PubMed ID: 17890210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
